Representation of Efavirenz-mediated Drug-Induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST)
Keywords: drug induced liver injury (DILI), efavirenz, human immunodeficiency virus (HIV), non-nucleoside reverse transcriptase inhibitor, Post-Approval/Generics, Quantitative Systems Toxicology (QST), SLP MIDD+ Virtual Conference, SLP2021MIDDSoftware: DILIsym®, GastroPlus®Conference: SLP MIDD+Division: DILIsym Services
Diane Longo, Senior Scientist, presents, “Representation of Efavirenz-mediated Drug-Induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST)”
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other agents to treat human immunodeficiency virus (HIV) infection. Efavirenz treatment is associated with a low frequency of serum enzyme elevations. To understand the hepatotoxicity mechanisms underlying clinically observed liver signals, efavirenz was represented in DILIsym®, a QST model of DILI.
This work was previously presented at ACoP 2020 Conference and re-presented at the SLP MIDD+ Virtual Conference March 3-4, 2021
